胃肠间质瘤靶向治疗及进展  

Recent advances and targeted therapy on gastrointestinal stromal tumor

作　　者：陈可绪[1,2] 梁汉霖[2] 彭杰文[2] 郑燕芳[1] 

机构地区：[1]南方医科大学,广东广州510000 [2]中山市人民医院肿瘤分院,广东中山528400

出　　处：《现代肿瘤医学》2017年第23期3910-3914,共5页Journal of Modern Oncology

基　　金：中山市人民医院博士后科研启动基金(编号:E2015690)

摘　　要：胃肠间质瘤是最常见的胃肠道肉瘤,大部分存在Kit、PDGFR突变,对靶向药物伊马替尼治疗有效率高。低危型的早期患者选择手术治疗有治愈机会,但对于中高危型及晚期患者,靶向治疗则占据十分重要的地位。不过伊马替尼治疗容易出现耐药。本文将详细阐述胃肠间质瘤各线靶向治疗,并对当前研究现状及发展作一综述。Gastrointestinal stromal tumor（GIST） is the most common mesenchymal tumor in digestive tract, a specific Kit or PDGFRA signaling driven tumor, which indicate effectiveness of imatinib mesylate. For early GIST or those estimated with low risk of recurrence pstients, surgically excision would be currative, but for moderate to high risk and unresectable patients,targeted therapy would be of great value. However,imatinib mesylate would develop resistance soon. The purpose of this paper is to set conclusions about the target therapy of different lines and to review the research of current and future state.

关 键 词：胃肠间质瘤 伊马替尼 靶向治疗 耐药 

分 类 号：R730.58[医药卫生—肿瘤]